Emisphere Technologies Inc. announced today that the company is introducing and launching its first commercially available product, oral Eligen B12 (100 mcg). This product has been specifically developed to help improve Vitamin B12 absorption and bioavailability with a patented formulation.

In a trial with healthy subjects conducted last year, Eligen B12 resulted in a ten-fold increase in peak serum B12 blood levels, a two-fold improvement in total bioavailability and a reduction in absorption time greater than 90% as compared to standard oral commercial formulations.

Eligen B12 has impressed others in the nutritional field. Dr. Michael Rothkopf, M.D., the director of Atlantic Health’s Metabolic Medicine and Weight Control Center, said, “Oral Eligen B12 is a scientific breakthrough that will help many individuals by increasing Vitamin B12 levels in the body. It has a different mechanism of action than other available formulations which will also prove to be a benefit.”

The company is

DrStockPick.com Stock Report!

Wednesday August 19, 2009

**************************************************************

Emisphere Technologies, Inc. (OTC BB: EMIS) today announced that it has received commitments from two institutional investors to purchase $4 million of securities in a registered direct offering. Emisphere entered into a securities purchase agreement with these investors pursuant to which Emisphere has agreed to sell an aggregate of 5,714,286 shares of its common stock and warrants to purchase up to 2,685,714 additional shares of its common stock. Each unit, consisting of one share of common stock and a warrant to purchase 0.47 of a share of common stock, will be sold for a purchase price of $0.70.

Lake Victoria Mining Company, Inc.